AngioDynamics Inc. (ANGO) to Release Quarterly Earnings on Wednesday
AngioDynamics Inc. (NASDAQ:ANGO) is scheduled to be announcing its earnings results before the market opens on Wednesday, October 5th. Analysts expect the company to announce earnings of $0.13 per share for the quarter. AngioDynamics has set its Q1 guidance at $0.11-0.14 EPS and its FY17 guidance at $0.62-0.65 EPS.
AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Wednesday, July 13th. The company reported $0.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. The business earned $93.40 million during the quarter, compared to analyst estimates of $88.64 million. AngioDynamics had a positive return on equity of 3.94% and a negative net margin of 12.57%. AngioDynamics’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 EPS. On average, analysts expect AngioDynamics to post $0.63 EPS for the current fiscal year and $0.73 EPS for the next fiscal year.
AngioDynamics Inc. (NASDAQ:ANGO) opened at 17.43 on Tuesday. AngioDynamics Inc. has a 52-week low of $9.71 and a 52-week high of $17.64. The company’s market capitalization is $634.84 million. The stock has a 50 day moving average price of $16.72 and a 200 day moving average price of $14.21.
In related news, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of AngioDynamics stock in a transaction on Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,763,420.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David F. Burgstahler sold 2,250,000 shares of AngioDynamics stock in a transaction on Friday, August 5th. The shares were sold at an average price of $14.62, for a total value of $32,895,000.00. Following the completion of the transaction, the director now owns 23,988 shares of the company’s stock, valued at $350,704.56. The disclosure for this sale can be found here. 1.88% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Panagora Asset Management Inc. raised its position in AngioDynamics by 53.5% in the second quarter. Panagora Asset Management Inc. now owns 31,077 shares of the company’s stock worth $447,000 after buying an additional 10,833 shares during the period. Guggenheim Capital LLC boosted its stake in AngioDynamics by 2.5% in the second quarter. Guggenheim Capital LLC now owns 78,480 shares of the company’s stock worth $1,128,000 after buying an additional 1,910 shares in the last quarter. Bridgeway Capital Management Inc. boosted its stake in AngioDynamics by 111.5% in the second quarter. Bridgeway Capital Management Inc. now owns 66,400 shares of the company’s stock worth $954,000 after buying an additional 35,000 shares in the last quarter. C M Bidwell & Associates Ltd. acquired a new stake in AngioDynamics during the second quarter worth $109,000. Finally, Parametric Portfolio Associates LLC boosted its stake in AngioDynamics by 1.1% in the second quarter. Parametric Portfolio Associates LLC now owns 127,592 shares of the company’s stock worth $1,833,000 after buying an additional 1,436 shares in the last quarter. Hedge funds and other institutional investors own 69.29% of the company’s stock.
Several research analysts have recently commented on the company. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, July 25th. KeyCorp set a $18.00 price target on AngioDynamics and gave the stock a “buy” rating in a research report on Monday, September 12th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $15.20.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Stock Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related stocks with our FREE daily email newsletter.